CD274 and non-small cell lung carcinoma: For example, the approval of certain drugs is based on specific thresholds for PD-L1 expression levels, such as the PD-L1 Tumor Proportion Score (TPS) of ≥ 1% when using pembrolizumab in patients with non-small cell lung cancer.